26 Oct, 2026 RNAi Roundtable: Brezosiran, An Investigational RNAi Therapeutic Targeting Exon 1 of the Huntingtin Gene to Slow Progression of Huntginton's Disease

On October 26, 2026, we hosted an online RNAi Roundtable to review progress with brezosiran, an investigational RNAi therapeutic targeting exon 1 of the huntingtin gene to slow progression of Huntington's disease.

Access the replay
View the presentation

Pushkal Garg, M.D.
Chief Research & Development Officer

Kevin Sloan, Ph.D.
Vice President, Development Programs, Brezosiran Program Lead

Gill Bates, Ph.D.
Professor of Molecular Neuroscience, Co-Director of the Huntington's Disease Centre, University College London

Toby Ferguson, M.D., Ph.D.
Senior Vice President, Neuroscience Therapeutic Area Head